Allergen immunotherapy on the way to product-based evaluation-a WAO statement.
Allergen immunotherapy on the way to product-based evaluation-a WAO statement.
复制标题
DOI：
10.1186/s40413-015-0078-8
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Passalacqua G
中科院分区：
文献类型：
--
作者：
Bachert C;Larché M;Bonini S;Canonica GW;Kündig T;Larenas-Linnemann D;Ledford D;Neffen H;Pawankar R;Passalacqua G
过敏原免疫疗法（AIT）广泛用于临床实践中用于由于吸入性过敏原而患有中度至重度过敏性鼻炎的患者，并且可以通过皮下（SCIT）和舌下途径（SLIT）递送。然而，个别AIT产品的证据质量是非常异质性的，并且将关于疗效和疾病改善作用的总体结论（“类效应”）扩展到所有AIT产品是不合理的。相比之下，每种产品都需要根据现有的研究结果进行单独评估，以证明每种过敏原和目标患者群体（儿童与成人，过敏性鼻炎与哮喘）的持续和疾病改善效果的有效性和具体声明。WAO打算支持目前的发展，以证据为基础的AIT，这最终将导致一个更有效的治疗过敏患者和适当的承认AIT。
Allergen immunotherapy (AIT) is widely used in clinical practice for patients with moderate to severe allergic rhinitis due to inhalant allergens and may be delivered via subcutaneous (SCIT) and sublingual routes (SLIT). However, the quality of evidence for individual AIT products is very heterogeneous, and extensions of overall conclusions (“class effects”) on the efficacy and disease-modifying effects to all AIT products are unjustified. In contrast, each product needs to be evaluated individually, based on available study results, to justify efficacy and specific claims on sustained and disease modifying effects per allergen and targeted patient group (children vs. adults, allergic rhinitis vs. asthma). WAO intends to support the current development to evidence-based AIT, which ultimately will lead to a more efficacious treatment of allergic patients and the appropriate recognition of AIT.